Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Certara, Inc. CERT
$20.50
-$0.48 (-2.33%)
На 18:03, 12 мая 2023
+17.07%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
3335134530.00000000
-
week52high
24.96
-
week52low
10.60
-
Revenue
335644000
-
P/E TTM
248
-
Beta
1.57238300
-
EPS
0.09000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | 25 авг 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 авг 2022 г. |
| Barclays | Overweight | Overweight | 17 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 10 авг 2022 г. |
| Berenberg | Buy | 08 сент 2022 г. | |
| Barclays | Overweight | Overweight | 06 окт 2022 г. |
| Credit Suisse | Outperform | Outperform | 14 ноя 2022 г. |
| Baird | Neutral | Outperform | 14 дек 2022 г. |
| Barclays | Overweight | Overweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Traynor Richard M. | D | 194564 | 15000 | 02 февр 2023 г. |
| EQT Avatar Parent L.P. | D | 0 | 29954521 | 08 дек 2022 г. |
| Pedersen Leif E | D | 175500 | 51223 | 22 ноя 2022 г. |
| SLAINE MASON P | D | 660322 | 245793 | 15 ноя 2022 г. |
| SLAINE MASON P | D | 906115 | 4207 | 14 ноя 2022 г. |
| WALSH MATTHEW M | D | 167901 | 12059 | 14 ноя 2022 г. |
| SMITH PATRICK F | D | 74859 | 2387 | 09 ноя 2022 г. |
| SMITH PATRICK F | D | 77246 | 1244 | 01 ноя 2022 г. |
| Virkler Drayton | A | 17440 | 17440 | 04 окт 2022 г. |
| Virkler Drayton | D | 6042 | 3021 | 30 сент 2022 г. |
Новостная лента
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
GlobeNewsWire
01 февр 2023 г. в 16:30
PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Wednesday, March 1st, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
CERT vs. PBYI: Which Stock Should Value Investors Buy Now?
Zacks Investment Research
09 янв 2023 г. в 12:48
CERT vs. PBYI: Which Stock Is the Better Value Option?
Why Certara Is A Buy For 2023
Seeking Alpha
06 дек 2022 г. в 07:57
Unlike Schrodinger, Certara posted a profit in the last quarter. Business momentum is accelerating as backlog grows.
Why Certara's Shares Rose 37.7% This Week
The Motley Fool
11 ноя 2022 г. в 16:28
The company, which helps other companies in their drug development, reported strong third-quarter numbers.
Certara, Inc. (CERT) Q3 Earnings Miss Estimates
Zacks Investment Research
07 ноя 2022 г. в 20:19
Certara, Inc. (CERT) delivered earnings and revenue surprises of -9.09% and 2.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?